Last reviewed · How we verify
LCB01-0371
At a glance
| Generic name | LCB01-0371 |
|---|---|
| Also known as | LCB01-0371 or placebo |
| Sponsor | LigaChem Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Vomiting
- Electrocardiogram QT prolonged
- Hypernatraemia
- Myalgia
- Haematuria
- Anemia
- Tachycardia
- Pyrexia
- Conjunctivitis
- Herpes zoster
- Soft tissue injury
Key clinical trials
- PanACEA - STEP2C -01 (PHASE2)
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB (PHASE2)
- PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) (PHASE2)
- Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex (PHASE2)
- A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia (PHASE2)
- Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches (PHASE1)
- A Mass Balance Study of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371-microtrace (PHASE1)
- A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LCB01-0371 CI brief — competitive landscape report
- LCB01-0371 updates RSS · CI watch RSS
- LigaChem Biosciences, Inc. portfolio CI